Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CLINICAL THERAPEUTICS40(1) · pp.83 · 2018
- 피인용
- Web of Science 25Scopus 32
- FWCI (Scopus)
- 1.38
- JCR IF
- JCR 2017 3.185
- ISSN
- 0149-2918
저자
- Kim, Chee Hae제1저자Department of Internal Medicine, Seoul National University Hospital, Cardiovascular Centre, Seoul, South Korea
- Han, Kyung AhDiabetes Center, Eulji University, Seoul Eulji hospital, Seoul, South Korea
- Yu, JaemyungKangnam Sacred Heart Hospital, Seoul, South Korea
- Lee, Sang HakCardiology Division, Yonsei University College of Medicine, Severance Cardiovascular Hospital, Seoul, South Korea
- Jeon, Hui KyungDepartment of Internal Medicine, Division of Cardiology, The Catholic University of Korea, Seoul, South Korea
- Kim, Sang HyunDepartment of Cardiology, Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea
- Kim, Seok YeonDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea
- Han, Ki HoonDepartments of Cardiology, Ischemic Heart Disease Center, Asan Medical Center Heart Institute, Seoul, South Korea
- Won, KyungheonDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea
- Kim, Dong-BinDepartment of Cardiology, Catholic University of Korea College of Medicine, Seoul, South Korea
- Lee, Kwang-JaeDepartment of Endocrinology, Daedong Hospital, Seoul, South Korea
- Min, KyungwanDiabetes Center, Eulji University, Seoul Eulji hospital, Seoul, South Korea
- Byun, Dong WonEndocrinology and Metabolism, Soonchunhyang University Hospital, Seoul, South Korea
- Lim, Sang-WookDepartment of Cardiology, Bundang Cha General Hospital, Seoul, South Korea
- Ahn, Chul WooDepartment of Internal Medicine, Gangnam Severance Hospital, Seoul, South Korea
- Kim, SeongHwanDivision of Cardiology, Department of Medicine, Korea University Ansan Hospital, Seoul, South Korea
- Hong, Young JoonHeart Center of Chonnam National University Hospital, Chonnam National University, Seoul, South Korea
- Sung, JidongDivision of Cardiology, Cardiac and Vascular Center, Samsung Medical Center, Seoul, South Korea
- Hur, Seung-HoDepartment of Cardiology, Keimyung University Dongsan Hospital, Daegu, South Korea
- Hong, Soon JunKorea University Medical Center, Korea University, Seoul, South Korea
- Lim, Hong-SeokDepartment of Cardiology, Ajou University School of Medicine, Suwon, South Korea
- Park, Ie ByungDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
- 김인주Department of Internal Medicine, Pusan National University College of Medicine, Busan, South Korea
- Lee, HyoungwooDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea
- Kim, Hyo-Soo교신저자Department of Internal Medicine, Seoul National University Hospital, Cardiovascular Centre, Seoul, South Korea
초록
Purpose: The purpose of this study was to examine the efficacy and safety of adding omega-3 fatty acids to rosuvastatin in patients with residual hypertriglyceridemia despite statin treatment. Methods: This study was a multicenter, randomized, double-blind, placebo-controlled study. After a 4-week run-in period of rosuvastatin treatment, the patients who had residual hypertriglyceridemia were randomized to receive rosuvastatin 20 mg/d plus omega-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) with a 1:1 ratio and were prescribed each medication for 8 weeks. Findings: A total of 201 patients were analyzed (mean [SD] age, 58.1 [10.7] years; 62.7% male). After 8 weeks of treatment, the percentage change from baseline in triglycerides (TGs) and non-HDL-C was significantly greater in the ROSUMEGA group than in the rosuvastatin group (TGs: -26.3% vs -11.4%, P < 0.001; non-HDL-C: -10.7% vs -2.2%, P = 0.001). In the linear regression analysis, the lipid-lowering effect of omega-3 fatty acids was greater when baseline TG or non-HDL-C levels were high and body mass index was low. The incidence of adverse events was not significantly different between the 2 groups. (C) 2018 The Authors. Published by Elsevier HS Journals, Inc.
키워드
combinationhypertriglyceridemianon-HDL-Comega-3 fatty acidsrosuvastatintriglyceridesDENSITY-LIPOPROTEIN CHOLESTEROLCORONARY-HEART-DISEASEESTER AMR101 THERAPYNON-HDL CHOLESTEROLCARDIOVASCULAR-DISEASEEICOSAPENTAENOIC ACIDHIGH-RISKTRIGLYCERIDE LEVELSMETABOLIC SYNDROMEFATTY-ACIDS
식별자
- Scopus EID
- 2-s2.0-85039991220
- WoS UID
- 000423137800010



로그인
연구물 목록으로